Diagnostic accuracy of ultrasound-guided fine needle aspiration biopsy for thyroid malignancy: systematic review and meta-analysis

Endocrine ◽  
2016 ◽  
Vol 53 (3) ◽  
pp. 651-661 ◽  
Author(s):  
Naykky Singh Ospina ◽  
Juan P. Brito ◽  
Spyridoula Maraka ◽  
Ana E. Espinosa de Ycaza ◽  
Rene Rodriguez-Gutierrez ◽  
...  
Keyword(s):  
Systematic Review ◽  
Diagnostic Accuracy ◽  
Fine Needle Aspiration ◽  
Fine Needle Aspiration Biopsy ◽  
Meta Analysis ◽  
Needle Aspiration ◽  
Aspiration Biopsy ◽  
Thyroid Malignancy ◽  
Ultrasound Guided ◽  
Fine Needle

Abstract #1039: Repeat Fine Needle Aspiration Biopsy for Bethesda III Thyroid Nodules: A Systematic Review and Meta-Analysis

2017 ◽  
Vol 23 ◽  
pp. 231-232
Author(s):  
Cesar Abuchaibe ◽  
Julie Hallanger-Johnson ◽  
Christine Chung ◽  
Bryan McIver ◽  
Pablo Valderrabano
Keyword(s):  
Systematic Review ◽  
Fine Needle Aspiration ◽  
Thyroid Nodules ◽  
Fine Needle Aspiration Biopsy ◽  
Meta Analysis ◽  
Needle Aspiration ◽  
Aspiration Biopsy ◽  
Fine Needle ◽  
Needle Aspiration Biopsy

Outcomes of Repeat Fine Needle Aspiration Biopsy for AUS/FLUS Thyroid Nodules. A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Ane Bayona ◽  
Patricia Benavent ◽  
Alfonso Muriel ◽  
Cesar Abuchaibe ◽  
Susan C Sharpe ◽  
...  
Keyword(s):  
Systematic Review ◽  
Fine Needle Aspiration ◽  
Thyroid Nodules ◽  
Fine Needle Aspiration Biopsy ◽  
Meta Analysis ◽  
Needle Aspiration ◽  
Aspiration Biopsy ◽  
Fine Needle ◽  
True Value ◽  
Summary Data

Objective: To determine the proportion of aspirates reclassified into each Bethesda category; and to assess the rates of malignancy in each of them on repeat fine needle aspiration biopsy (RFNA) following an AUS/FLUS diagnosis. Design: Systematic review and meta-analysis Methods: On February 2019, Pubmed/MEDLINE, EMBASE, WoS and the Cochrane Library were searched for articles published from January 1, 2007. All studies published in English describing RFNA outcomes in AUS/FLUS nodules were included. PRISMA and MOOSE guidelines were followed. Five investigators independently assessed the eligibility of the studies. Two investigators extracted summary data and assessed risk of bias. Data were pooled using a random-effects model. The rate of malignancy was calculated on resected nodules only (upper limit of true value); and considering benign all unresected nodules (lower limit of true value). The protocol was registered in PROSPERO (CRD42019123114). Results: Of 2937 retrieved studies, 27 were eligible. The meta-analysis was conducted on summary data of 3932 AUS/FLUS thyroid nodules with RFNA. RFNA cytology would reclassify into categories I through VI of Bethesda: 4% (3%,5%); 48% (43%,54%); 26% (20%,32%); 4% (3%,6%); 5% (3%,6%); and 2% (1%,2%) of AUS/FLUS nodules. Malignancy rates of resected nodules were 24% (9%,38%), 4% (1%,7%), 40% (28%,52%), 37% (27%,47%), 79% (69%,90%) and 99% (95%,100%) for categories I through VI of Bethesda. There was high heterogeneity in these data. Conclusions: RFNA reclassified two thirds of the AUS/FLUS specimens into a more definitive cytological category, with a benign call rate of nearly 50% and a negative predictive value greater than 96%.

Sign in / Sign up

Export Citation Format

Share Document